AzTrials
AzTrials

Neuroendocrine TumorsSwissNETNCT01039922

SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

An observational study of Neuroendocrine Tumors and Carcinoid Tumor, run by Insel Gruppe AG, University Hospital Bern at 55 sites in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. Read more about this study

Who is it for?
Any age
Conditions the study is for
Neuroendocrine Tumors, Carcinoid Tumor
How many people
1,245 participants
Where
55 sitesSwitzerland
Study dates
Jan 2008to 31 Aug 2025
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients will be selected either through the report of a pathological institute or of any medical doctor within Switzerland treating patients with neuroendocrine tumours.

Who may be able to join

  • Neuroendocrine tumor irrespective of primary tumor location
  • Diagnosis in Switzerland
  • Given informed consent

Who cannot join

None listed.

Trial locations and contacts

55 sites in 1 country.

55 sites in 1 country

Switzerland55 sites

  • Kantonsspital Aarau

    Aarau

  • Spitalnetz Bern Aarberg

    Aarberg

  • Bezirksspital Affoltern

    Affoltern am Albis

  • Kantonsspital Uri, Altdorf

    Altdorf

  • St. Claraspital

    Basel

  • Universitätsspital Basel

    Basel

  • Istituto oncologico della Svizzera italiana

    Bellinzona

  • Div. of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital

    Bern, 3010

  • Spital Tiefenau, Spitalnetz Bern

    Bern

  • Zieglerspital Bern

    Bern

  • Spitalzentrum Biel - Bienne

    Biel

  • Kantonsspital Bruderholz

    Bruderholz

  • Regionsspital Emmental

    Burgdorf

  • Kantonsspital Chur

    Chur

  • Private practise Dr. Mannhart

    Churwalden

  • Hôpital du Jura

    Delémont

  • Spital Dornach

    Dornach

  • Regionalspital Einsiedeln

    Einsiedeln

  • Hôpitaux Universitaires de Genève

    Geneva

  • Spital Grabs

    Grabs

  • See-Spital Horgen

    Horgen

  • Spital Zimmerberg

    Horgen

  • Fmi Spital Interlaken

    Interlaken

  • Spital Lachen

    Lachen

  • Spital Region Oberaargau

    Langenthal

  • Kantonsspital Laufen

    Laufen

  • Centre hospitalier universitaire vaudois, CHUV

    Lausanne

  • Kantonsspital Liestal

    Liestal

  • Hirslandenklinik St. Anna

    Lucerne

  • Kantonsspital Luzern

    Lucerne

  • Kantonsspital Sursee, Luzern

    Lucerne

  • Kreisspital Männedorf

    Männedorf

  • Kantonsspital Münsterlingen

    Münsterlingen

  • Kantonsspital Olten

    Olten

  • Gesundheitszentrum Fricktal

    Rheinfelden

  • Kantonsspital St. Gallen

    Sankt Gallen

  • Kantonsspital Obwalden

    Sarnen

  • Spital Limmattal

    Schlieren

  • Spital Schwyz

    Schwyz

  • Privatpraxis Dr. H.J. Poths

    Seuzach Dorf

  • Centre hospitalier du centre du Valais

    Sion

  • Bürgerspital Solothurn

    Solothurn

  • Kantonsspital Nidwalden

    Stans

  • Thun Spital STS AG

    Thun

  • Spital Uster

    Uster

  • Regionalspital Visp

    Visp

  • Kantonsspital Winterthur

    Winterthur

  • Kantonsspital Wolhusen

    Wolhusen

  • Spital Zollikerberg

    Zollikerberg

  • Zuger Kantonsspital AG

    Zug

  • Pathologie Medica Zürich

    Zurich

  • Stadtspital Triemli

    Zurich

  • Stadtspital Waid

    Zurich

  • Universitätsspital Zürich

    Zurich

  • STS AG Spital Zweisimmen

    Zweisimmen

Other trials in Switzerland

About this study

Official title: SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. So far, there is still uncertainty about the cell biology and mechanistic regulation of these tumours. Therefore targeted treatment is limited and management challenging. Treatment options include surgery, medical and ablative therapy, and more recently peptide-receptor radionuclide therapy. In order to better understand the characteristics of GEP-NETs and to evaluate treatment strategies, the SwissNET registry aims at the collection of data from patients presenting with a GEP-NET in Switzerland. Data will be entered prospectively and anonymized in a specifically designed database after the patient has given informed consent. All hospitals and general practitioners are invited to report on patients with a GEP-NET diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focussing on types of GEP-NETs, treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate), thereby contributing to the better understanding of these tumours.

Read the detailed description

Background

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are generally classified as rare diseases. Little is known about their cell biology and their mechanistic regulation. During the last years, the incidence of GEP-NETs is continuously increasing worldwide. In parallel, novel treatment options are currently evaluated which may substantially improve prognosis of patients with NETs. Data on such tumours in Switzerland, however, is scarce and treatment strategies vary throughout the country.

Objective

To systematically and prospectively collect clinical information of patients with GEP-NETs in Switzerland based on a histologically confirmed diagnosis.

Methods

All NETs of both, gastrointestinal and pulmonary origin are included provided that patients have given informed consent. Data will be entered prospectively and anonymised in a specifically designed database. Contributing centres and general practitioners are visited by a study nurse, patient files are analysed and data is transferred to the database. In case of conflicting evidence, questions are resolved in collaboration with a review board of SwissNET. Evaluation of treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate) will take place within regular time frames.

Keywords
Neuroendocrine Tumors, Registries
Medical subject headings
Neuroendocrine Tumors, Carcinoid Tumor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01039922
Study groupRoleWhat they receive
1Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Tumor-related mortality

    Measured: Every 5 years

Secondary outcomes (2)

  1. Incidence of GEP-NET in Switzerland

    Measured: Every 5 years

  2. Effect of specific treatment strategies

    Measured: Every 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Dec 2009 (estimated)
  2. Study startJan 2008
  3. Primary completion31 Aug 2025
  4. Study completion31 Aug 2025

Why it stopped: The register will no longer be maintained on a prospective basis

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,245 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01039922
Sponsor's protocol ID
BAG 035.0002-20/19
Other IDs
395/2014
Acronym
SwissNET
Status last verified
Sep 2026
First submitted
24 Dec 2009
Last updated
11 Sep 2026
Results posted
No
Data monitoring committee
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in